Abstract | BACKGROUND: METHODS: A 12-week, randomized, open-label cross-over study was conducted in 16 patients with ACOS to compare the effectiveness of once-daily FF/VI 200/25 μg vs. twice-daily fluticasone propionate/salmeterol (FP/SAL) 500/50 μg. The study period included a 4-week run-in, the first 4-week treatment, and the second 4-week treatment. Respiratory functions, including forced expiratory volume in 1 s (FEV1) and respiratory impedance using the forced oscillation technique (FOT), were measured, as was fractional exhaled nitric oxide (FeNO). A COPD assessment test (CAT) scores and asthma control test (ACT) scores were recorded 0, 4, and 8 weeks after randomization. RESULTS: The mean values for the FEV1 were 1.33 (±0.29) L in the run-in period, 1.38 (±0.39) L after the FP/SAL treatment period, and 1.47 (±0.38) L after the FF/VI treatment period. The FEV1 value after the FF/VI treatment was significantly greater than the value after the run-in period (p < 0.01). FOT parameters, FeNO levels, CAT scores, ACT scores, and other blood tests were not significantly different during the run-in period, the FP/SAL treatment period, and the FF/VI treatment period. CONCLUSIONS: FF/VI, the first once-daily ICS/LABA, can provide substantial improvement in lung functions, indicating that FF/VI should be considered for the regular treatment of ACOS.
|
Authors | Yoshihisa Ishiura, Masaki Fujimura, Yasutaka Shiba, Noriyuki Ohkura, Johsuke Hara, Kazuo Kasahara |
Journal | Pulmonary pharmacology & therapeutics
(Pulm Pharmacol Ther)
Vol. 35
Pg. 28-33
(Dec 2015)
ISSN: 1522-9629 [Electronic] England |
PMID | 26497109
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- Androstadienes
- Anti-Asthmatic Agents
- Benzyl Alcohols
- Chlorobenzenes
- Drug Combinations
- Fluticasone-Salmeterol Drug Combination
- vilanterol
- Nitric Oxide
- fluticasone furoate
|
Topics |
- Aged
- Aged, 80 and over
- Androstadienes
(administration & dosage, therapeutic use)
- Anti-Asthmatic Agents
(therapeutic use)
- Asthma
(complications, drug therapy)
- Benzyl Alcohols
(administration & dosage, therapeutic use)
- Chlorobenzenes
(administration & dosage, therapeutic use)
- Cross-Over Studies
- Double-Blind Method
- Drug Combinations
- Female
- Fluticasone-Salmeterol Drug Combination
(therapeutic use)
- Forced Expiratory Volume
- Humans
- Male
- Middle Aged
- Nitric Oxide
(metabolism)
- Pulmonary Disease, Chronic Obstructive
(complications, drug therapy)
- Respiratory Function Tests
|